Research
Hormonal
Estrogen (E2) reduces adiposity and adipocyte size independently of energy intake by down-regulating lipogenic genes (SREBP-1c, FAS, ACC-1) and up-regulating lipid oxidation pathways (PPAR-alpha, AMPK) in skeletal muscle and adipose tissue.
If you are post-menopausal or have low estrogen, you may experience increased abdominal fat storage due to metabolic changes, not just eating more. Estrogen replacement therapy can help maintain leanness by shifting your body to burn fat rather than store it, acting directly on your muscles and fat cells.
GoodSupportsHIGH confidence
These data demonstrate that chronic estrogen treatment promotes smaller adipocytes and reduced adipose mass independently of reduced energy intake in OVX mice.
Why this rating
High-quality controlled animal study with pair-feeding controls to isolate metabolic effects from caloric intake.
Source
Estrogen Regulation of Adiposity and Fuel Partitioning
Tara M. D'Eon et al. · Journal of Biological Chemistry · 2005
DOI 10.1074/jbc.m507339200
mechanism_only · n=9Cited 511×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Estrogen rapidly activates AMP-activated protein kinase (AMPK) in skeletal muscle via non-genomic mechanisms, promoting fat oxidation and down-regulating lipogenesis.Good
- Estrogen increases perilipin protein levels in adipocytes, which suppresses basal lipolysis but significantly enhances catecholamine-stimulated lipolysis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →